Literature DB >> 18637089

Predictors of patient-assessed illness severity in irritable bowel syndrome.

Brennan Spiegel1, Amy Strickland, Bruce D Naliboff, Emeran A Mayer, Lin Chang.   

Abstract

BACKGROUND: Conceptual models suggest that "irritable bowel syndrome (IBS) severity" is a multidimensional outcome that is related to, yet distinct from, health-related quality of life (HRQOL). Existing severity questionnaires are largely based on physician rather than patient-based ratings. Since severity is a patient-centered outcome, it is essential that future instruments are based on patients' self-perceptions of severity. We measured patient-derived predictors of severity in a large cohort of IBS patients.
METHODS: We performed a cross-sectional analysis in 755 IBS patients recruited at a university-based center. Subjects completed a bowel symptom questionnaire, SCL-90, and SF-36. The main outcome was patient-assessed "overall severity of gastrointestinal symptoms," as measured on a 0-20 scale (20 = most severe). We first developed a conceptual model of IBS, and then performed bivariate analyses to identify biopsychosocial predictors of severity. We then entered significant predictors into a multivariable model to measure the independent association of each predictor with severity.
RESULTS: Six factors predicted severity: (a) abdominal pain rating (P < 0.001); (b) belief that "something serious is wrong with body" (P < 0.001); (c) straining with defecation (P= 0.001); (d) myalgias (P= 0.02); (e) urgency with defecation (P= 0.03); and (f) bloating (P= 0.05). Severity correlated highly with HRQOL in bivariate, but not multivariate, analysis.
CONCLUSION: Patient-derived severity in IBS is related to, yet distinct from, generic HRQOL. IBS severity is predicted by abdominal pain, bloating, straining, urgency, myalgias, and disease-related concern. These symptoms fall along both poles of the "brain-gut axis," indicating that a full assessment of patient severity must include a balanced biopsychosocial history.

Entities:  

Mesh:

Year:  2008        PMID: 18637089      PMCID: PMC2949074          DOI: 10.1111/j.1572-0241.2008.01997.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  49 in total

Review 1.  Assessing global pain severity by self-report in clinical and health services research.

Authors:  M Von Korff; M P Jensen; P Karoly
Journal:  Spine (Phila Pa 1976)       Date:  2000-12-15       Impact factor: 3.468

2.  Patient knowledge and educational needs in irritable bowel syndrome.

Authors:  M A O'Sullivan; N Mahmud; D P Kelleher; E Lovett; C A O'Morain
Journal:  Eur J Gastroenterol Hepatol       Date:  2000-01       Impact factor: 2.566

3.  The understanding of their illness amongst people with irritable bowel syndrome: a Q methodological study.

Authors:  P H Stenner; C P Dancey; S Watts
Journal:  Soc Sci Med       Date:  2000-08       Impact factor: 4.634

4.  The patient's perspective of irritable bowel syndrome.

Authors:  S Bertram; M Kurland; E Lydick; G R Locke; B P Yawn
Journal:  J Fam Pract       Date:  2001-06       Impact factor: 0.493

Review 5.  Evolving pathophysiological model of functional gastrointestinal disorders: implications for treatment.

Authors:  Emeran A Mayer; Bruce D Naliboff; Lin Chang
Journal:  Eur J Surg Suppl       Date:  2002

6.  Effects of coping on health outcome among women with gastrointestinal disorders.

Authors:  D A Drossman; J Leserman; Z Li; F Keefe; Y J Hu; T C Toomey
Journal:  Psychosom Med       Date:  2000 May-Jun       Impact factor: 4.312

7.  Medical and lay views of irritable bowel syndrome.

Authors:  M Dixon-Woods; S Critchley
Journal:  Fam Pract       Date:  2000-04       Impact factor: 2.267

8.  Fibromyalgia in the irritable bowel syndrome: studies of prevalence and clinical implications.

Authors:  A D Sperber; Y Atzmon; L Neumann; I Weisberg; Y Shalit; M Abu-Shakrah; A Fich; D Buskila
Journal:  Am J Gastroenterol       Date:  1999-12       Impact factor: 10.864

9.  Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire.

Authors:  D A Drossman; D L Patrick; W E Whitehead; B B Toner; N E Diamant; Y Hu; H Jia; S I Bangdiwala
Journal:  Am J Gastroenterol       Date:  2000-04       Impact factor: 10.864

10.  Use of the Functional Bowel Disorder Severity Index (FBDSI) in a study of patients with the irritable bowel syndrome and fibromyalgia.

Authors:  A D Sperber; S Carmel; Y Atzmon; I Weisberg; Y Shalit; L Neumann; A Fich; M Friger; D Buskila
Journal:  Am J Gastroenterol       Date:  2000-04       Impact factor: 10.864

View more
  43 in total

Review 1.  Diagnosis and management of IBS.

Authors:  Sarah Khan; Lin Chang
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-10       Impact factor: 46.802

Review 2.  Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles.

Authors:  Michael Camilleri; Lin Chang
Journal:  Gastroenterology       Date:  2008-10-09       Impact factor: 22.682

3.  Psychometric evaluation of patient-reported outcomes in irritable bowel syndrome randomized controlled trials: a Rome Foundation report.

Authors:  Brennan Spiegel; Michael Camilleri; Roger Bolus; Viola Andresen; William D Chey; Sheri Fehnel; Allen Mangel; Nicholas J Talley; William E Whitehead
Journal:  Gastroenterology       Date:  2009-08-23       Impact factor: 22.682

4.  Visceral sensitivity as a mediator of outcome in the treatment of irritable bowel syndrome.

Authors:  Kate Wolitzky-Taylor; Michelle G Craske; Jennifer S Labus; Emeran A Mayer; Bruce D Naliboff
Journal:  Behav Res Ther       Date:  2012-06-23

5.  Understanding gastrointestinal distress: a framework for clinical practice.

Authors:  Brennan M R Spiegel; Dinesh Khanna; Roger Bolus; Nikhil Agarwal; Puja Khanna; Lin Chang
Journal:  Am J Gastroenterol       Date:  2011-03       Impact factor: 10.864

6.  A cognitive-behavioral treatment for irritable bowel syndrome using interoceptive exposure to visceral sensations.

Authors:  Michelle G Craske; Kate B Wolitzky-Taylor; Jennifer Labus; Stephen Wu; Michael Frese; Emeran A Mayer; Bruce D Naliboff
Journal:  Behav Res Ther       Date:  2011-04-19

7.  Conditioned pain modulation in women with irritable bowel syndrome.

Authors:  Monica E Jarrett; Robert J Shulman; Kevin C Cain; Wimon Deechakawan; Lynne T Smith; Philippe Richebé; Margaret Eugenio; Margaret M Heitkemper
Journal:  Biol Res Nurs       Date:  2014-01-24       Impact factor: 2.522

8.  Type, rather than number, of mental and physical comorbidities increases the severity of symptoms in patients with irritable bowel syndrome.

Authors:  Jeffrey M Lackner; Chang-Xing Ma; Laurie Keefer; Darren M Brenner; Gregory D Gudleski; Nikhil Satchidanand; Rebecca Firth; Michael D Sitrin; Leonard Katz; Susan S Krasner; Sarah K Ballou; Bruce D Naliboff; Emeran A Mayer
Journal:  Clin Gastroenterol Hepatol       Date:  2013-03-21       Impact factor: 11.382

9.  Lubiprostone: evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndrome.

Authors:  Tisha N Lunsford; Lucinda A Harris
Journal:  Int J Womens Health       Date:  2010-10-27

10.  Developing valid and reliable health utilities in irritable bowel syndrome: results from the IBS PROOF Cohort.

Authors:  Brennan Spiegel; Lucinda Harris; Susan Lucak; Emeran Mayer; Bruce Naliboff; Roger Bolus; Eric Esrailian; William D Chey; Anthony Lembo; Hetal Karsan; Kirsten Tillisch; Gareth Dulai; Jennifer Talley; Lin Chang
Journal:  Am J Gastroenterol       Date:  2009-06-02       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.